Treatment response in first-episode schizophrenia

Clinical Psychopharmacology and Neuroscience

Volumn 10, Issue 2, 2012, Pages 78-87

  Schennach, Rebecca ^a   Riedel, Michael ^a   Musil, Richard ^a   Möller, Hans Jürgen ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Course of illness; First episode schizophrenia; Outcome; Predictors; Response; Treatment interventions

Indexed keywords

AMISULPRIDE; CATECHOL METHYLTRANSFERASE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

BRIEF PSYCHIATRIC RATING SCALE; CLINICAL GLOBAL IMPRESSION SCALE; COGNITIVE THERAPY; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; ELECTROCONVULSIVE THERAPY; ELECTROENCEPHALOGRAPHY; FIRST EPISODE OF SCHIZOPHRENIA; FIRST EPISODE SCHIZOPHRENIA; HUMAN; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PHARMACOGENETICS; POSITIVE AND NEGATIVE SYNDROME SCALE; PREDICTIVE VALUE; PROGNOSIS; PSYCHOTHERAPY; REVIEW; SCHEDULE FOR AFFECTIVE DISORDERS AND SCHIZOPHRENIA; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84865818513     PISSN: 17381088     EISSN: 20934327     Source Type: Journal    
DOI: 10.9758/cpn.2012.10.2.78     Document Type: Review

References (80)

1. Frangou S, Byrne P. How to manage the first episode of schizophrenia. BMJ 2000321:522-523
2. Redmond C, Larkin M, Harrop C. The personal meaning of romantic relationships for young people with psychosis. Clin Child Psychol Psychiatry 201015:151-170
3. Schnabel R, Friedel H, Erfurth A, Angermayer M, Clouth J, Eichmann F. Predisposing factors for early retirement in patients with schizophrenia in Germany. Eur J Health Econ 2008;9:265-274. (Pubitemid 351962400)
4. Harrison G, Hopper K, Craig T, Laska E, Siegel C, Wanderling J, et al. Recovery from psychotic illness: a 15- and 25-year international follow-up study. Br J Psychiatry 2001;178:506-517. (Pubitemid 32531743)
5. Loebel AD, Lieberman JA, Alvir JM, Mayerhoff DI, Geisler SH, Szymanski SR. Duration of psychosis and outcome in first-episode schizophrenia. Am J Psychiatry 1992149:1183-1188
6. International Early Psychosis Association Writing Group. International clinical practice guidelines for early psychosis. Br J Psychiatry Suppl 200548:s120-s124.
7. Lambert M, Naber D, Huber CG. Management of incomplete remission and treatment resistance in first-episode psychosis. Expert Opin Pharmacother 20089:2039-2051
8. Jäger M, Riedel M, Messer T, Laux G, Pfeiffer H, Naber D, et al. Psychopathological characteristics and treatment response of first episode compared with multiple episode schizophrenic disorders. Eur Arch Psychiatry Clin Neurosci 2007257:47-53
9. Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Möller HJ; WFSBP Task Force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia. World J Biol Psychiatry 20056:132-191
10. Robinson DG, Woerner MG, Alvir JM, Geisler S, Koreen A, Sheitman B, et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 1999;156:544-549. (Pubitemid 29162974)
11. Emsley R, Rabinowitz J, Medori R. Time course for antipsychotic treatment response in first-episode schizophrenia. Am J Psychiatry 2006;163:743-745. (Pubitemid 44464590)
12. Birchwood M, Todd P, Jackson C. Early intervention in psychosis. The critical period hypothesis. Br J Psychiatry Suppl 1998;172:53-59. (Pubitemid 28258899)
13. McGlashan TH. A selective review of recent North American long-term followup studies of schizophrenia. Schizophr Bull 1988;14:515-542. (Pubitemid 19129692)
14. Leucht S, Kane JM. Measurement-based psychiatry: definitions of response, remission, stability, and relapse in schizophrenia. J Clin Psychiatry 2006;67:1813-1814. (Pubitemid 44955164)
15. Leucht S, Davis JM, Engel RR, Kane JM, Wagenpfeil S. Defining 'response' in antipsychotic drug trials: recommendations for the use of scale-derived cutoffs. Neuropsychopharmacology 2007;32:1903-1910. (Pubitemid 47258518)
16. Lieberman J, Jody D, Geisler S, Alvir J, Loebel A, Szymanski S, et al. Time course and biologic correlates of treatment response in first-episode schizophrenia. Arch Gen Psychiatry 1993;50:369-376. (Pubitemid 23143126)
17. Emsley RA. Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Risperidone Working Group. Schizophr Bull 1999;25:721-729. (Pubitemid 30013554)
18. Sanger TM, Lieberman JA, Tohen M, Grundy S, Beasley C Jr, Tollefson GD. Olanzapine versus haloperidol treatment in first-episode psychosis. Am J Psychiatry 1999;156:79-87. (Pubitemid 29034883)
19. Agid O, Kapur S, Arenovich T, Zipursky RB. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiatry 2003;60:1228-1235. (Pubitemid 37494076)
20. Leucht S, Busch R, Hamann J, Kissling W, Kane JM. Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended. Biol Psychiatry 2005;57:1543-1549. (Pubitemid 40805384)
21. Kinon BJ, Chen L, Ascher-Svanum H, Stauffer VL, Kollack-Walker S, Sniadecki JL, et al. Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia. Schizophr Res 2008102:230-240
22. Kinon BJ, Chen L, Ascher-Svanum H, Stauffer VL, Kollack-Walker S, Zhou W, et al. Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia. Neuropsychopharmacology 201035:581-590
23. Derks EM, Fleischhacker WW, Boter H, Peuskens J, Kahn RS; EUFEST Study Group. Antipsychotic drug treatment in first-episode psychosis: should patients be switched to a different antipsychotic drug after 2, 4, or 6 weeks of nonresponse? J Clin Psychopharmacol 201030:176-180
24. Gallego JA, Robinson DG, Sevy SM, Napolitano B, McCormack J, Lesser ML, et al. Time to treatment response in first-episode schizophrenia: should acute treatment trials last several months? J Clin Psychiatry 201172:1691-1696
25. Schennach-Wolff R, Seemüller FH, Mayr A, Maier W, Klingberg S, Heuser I, et al. An early improvement threshold to predict response and remission in first-episode schizophrenia. Br J Psychiatry 2010196:460-466
26. Schennach R, Riesbeck M, Mayr A, Seemüller F, Maier W, Klingberg S, et al. Should early improvement be re-defined to better predict the maintenance of response in FES patients? Acta Psychiatrica Scandinavic 2012[In press].
27. Silvestri S, Seeman MV, Negrete JC, Houle S, Shammi CM, Remington GJ, et al. Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study. Psychopharmacology (Berl) 2000152:174-180
28. Deng MY, McAlonan GM, Cheung C, Chiu CP, Law CW, Cheung V, et al. A naturalistic study of grey matter volume increase after early treatment in anti-psychotic naïve, newly diagnosed schizophrenia. Psychopharmacology (Berl) 2009206:437-446
29. Dolzan V, Serretti A, Mandelli L, Koprivsek J, Kastelic M, Plesnicar BK. Acute antipyschotic efficacy and side effects in schizophrenia: association with serotonin transporter promoter genotypes. Prog Neuropsychopharmacol Biol Psychiatry 200832:1562-1566
30. Rasmussen H, Ebdrup BH, Erritzoe D, Aggernaes B, Oranje B, Kalbitzer J, et al. Serotonin2A receptor blockade and clinical effect in first-episode schizophrenia patients treated with quetiapine. Psychopharmacology (Berl) 2011213:583-592
31. Ikeda M, Yamanouchi Y, Kinoshita Y, Kitajima T, Yoshimura R, Hashimoto S, et al. Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia. Pharmacogenomics 20089:1437-1443
32. Lencz T, Robinson DG, Xu K, Ekholm J, Sevy S, Gunduz-Bruce H, et al. DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients. Am J Psychiatry 2006;163:529-531. (Pubitemid 44469398)
33. Pelayo-Terán JM, Pérez-Iglesias R, Vázquez-Bourgon J, Mata I, Carrasco-Marín E, Vázquez-Barquero JL, et al. Catechol-O-methyltransferase Val158Met polymorphism and negative symptoms after acute antipsychotic treatment in first-episode non-affective psychosis. Psychiatry Res 2011185:286-289
34. Kapur S, Zipursky R, Jones C, Remington G, Houle S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000;157:514-520. (Pubitemid 30191189)
35. Szeszko PR, Narr KL, Phillips OR, McCormack J, Sevy S, Gunduz-Bruce H, et al. Magnetic resonance imaging predictors of treatment response in first-episode schizophrenia. Schizophr Bull 201238:569-578
36. Garner B, Berger GE, Nicolo JP, Mackinnon A, Wood SJ, Pariante CM, et al. Pituitary volume and early treatment response in drug-naïve first-episode psychosis patients. Schizophr Res 2009113:65-71
37. Belvederi Murri M, Pariante CM, Dazzan P, Hepgul N, Papadopoulos AS, Zunszain P, et al. Hypothalamic-pituitary-adrenal axis and clinical symptoms in first-episode psychosis. Psychoneuroendocrinology 201237:629-644
38. van Venrooij JA, Fluitman SB, Lijmer JG, Kavelaars A, Heijnen CJ, Westenberg HG, et al. Impaired neuroendocrine and immune response to acute stress in medication-naive patients with a first episode of psychosis. Schizophr Bull 201238:272-279
39. Merlo MC, Kleinlogel H, Koukkou M. Differences in the EEG profiles of early and late responders to antipsychotic treatment in first-episode, drug-naive psychotic patients. Schizophr Res 1998;30:221-228. (Pubitemid 28189554)
40. McGlashan TH. Duration of untreated psychosis in first-episode schizophrenia: marker or determinant of course? Biol Psychiatry 1999;46:899-907. (Pubitemid 29452981)
41. Norman RM, Malla AK. Duration of untreated psychosis: a critical examination of the concept and its importance. Psychol Med 2001;31:381-400. (Pubitemid 32294037)
42. Addington J, Van Mastrigt S, Addington D. Duration of untreated psychosis: impact on 2-year outcome. Psychol Med 2004;34:277-284. (Pubitemid 38239635)
43. de Haan L, Linszen DH, Lenior ME, de Win ED, Gorsira R. Duration of untreated psychosis and outcome of schizophrenia: delay in intensive psychosocial treatment versus delay in treatment with antipsychotic medication. Schizophr Bull 2003;29:341-348. (Pubitemid 37187696)
44. Bottlender R, Sato T, Jäger M, Wegener U, Wittmann J, Strauss A, et al. The impact of the duration of untreated psychosis prior to first psychiatric admission on the 15-year outcome in schizophrenia. Schizophr Res 2003;62:37-44. (Pubitemid 36603320)
45. Larsen TK, Moe LC, Vibe-Hansen L, Johannessen JO. Premorbid functioning versus duration of untreated psychosis in 1 year outcome in first-episode psychosis. Schizophr Res 200045:1-9
46. Crespo-Facorro B, Pelayo-Terán JM, Pérez-Iglesias R, Ramírez-Bonilla M, Martínez-García O, Pardo-García G, et al. Predictors of acute treatment response in patients with a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables. J Psychiatr Res 200741:659-666
47. Verdoux H, Liraud F, Bergey C, Assens F, Abalan F, van Os J. Is the association between duration of untreated psychosis and outcome confounded? A two year follow-up study of first-admitted patients. Schizophr Res 2001;49:231-241. (Pubitemid 32453224)
48. Perkins D, Lieberman J, Gu H, Tohen M, McEvoy J, Green A, et al HGDH Research Group. Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders. Br J Psychiatry 2004;185:18-24. (Pubitemid 38951625)
49. Schimmelmann BG, Huber CG, Lambert M, Cotton S, McGorry PD, Conus P. Impact of duration of untreated psychosis on pre-treatment, baseline, and outcome characteristics in an epidemiological first-episode psychosis cohort. J Psychiatr Res 200842:982-990
50. Cesková E, Prikryl R, Kaspárek T, Ondrusová M. Psychopathology and treatment responsiveness of patients with first-episode schizophrenia. Neuropsychiatr Dis Treat 20051:179-185
51. Addington J, Leriger E, Addington D. Symptom outcome 1 year after admission to an early psychosis program. Can J Psychiatry 2003;48:204-207. (Pubitemid 36596949)
52. Schennach-Wolff R, Jäger M, Mayr A, Meyer S, Kühn KU, Klingberg S, et al. Predictors of response and remission in the acute treatment of first-episode schizophrenia patients - is it all about early response? Eur Neuropsychopharmacol 201121:370-378
53. Drake RJ, Dunn G, Tarrier N, Bentall RP, Haddock G, Lewis SW. Insight as a predictor of the outcome of first-episode nonaffective psychosis in a prospective cohort study in England. J Clin Psychiatry 2007;68:81-86. (Pubitemid 46220128)
54. Prikryl R, Ceskova E, Kasparek T, Kucerova H. Neurological soft signs and their relationship to 1-year outcome in first-episode schizophrenia. Eur Psychiatry 2007;22:499-504. (Pubitemid 350087649)
55. Oosthuizen P, Emsley R, Jadri Turner H, Keyter N. A randomized, controlled comparison of the efficacy and tolerability of low and high doses of haloperidol in the treatment of first-episode psychosis. Int J Neuropsychopharmacol 2004;7:125-131. (Pubitemid 38823279)
56. Robinson DG, Woerner MG, Delman HM, Kane JM. Pharmacological treatments for first-episode schizophrenia. Schizophr Bull 2005;31:705-722. (Pubitemid 41253320)
57. Kinon BJ, Lieberman JA. Mechanisms of action of atypical antipsychotic drugs: a critical analysis. Psychopharmacology (Berl) 1996;124:2-34. (Pubitemid 26111436)
58. Möller HJ. Management of the negative symptoms of schizophrenia: new treatment options. CNS Drugs 200317:793-823
59. Möller HJ. State of the art of drug treatment of schizophrenia and the future position of the novel/atypical antipsychotics. World J Biol Psychiatry 20001:204-214
60. Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE, Kahn R, et al HGDH Study Group. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry 2003;160:1396-1404. (Pubitemid 41070913)
61. Schooler N, Rabinowitz J, Davidson M, Emsley R, Harvey PD, Kopala L, et al Early Psychosis Global Working Group. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry 2005;162:947-953. (Pubitemid 40676208)
62. Möller HJ, Riedel M, Jäger M, Wickelmaier F, Maier W, Kühn KU, et al. Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia. Int J Neuropsychopharmacol 200811:985-997
63. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, et al; EUFEST study group. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008;371:1085-1097. (Pubitemid 351418005)
64. Boter H, Peuskens J, Libiger J, Fleischhacker WW, Davidson M, Galderisi S, et al; EUFEST study group. Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST). Schizophr Res 2009115:97-103
65. Crossley NA, Constante M, McGuire P, Power P. Efficacy of atypical v. typical antipsychotics in the treatment of early psychosis: meta-analysis. Br J Psychiatry 2010196:434-439
66. Rummel C, Hamann J, Kissling W, Leucht S. New generation antipsychotics for first episode schizophrenia. Cochrane Database Syst Rev 2003(4):CD004410.
67. Lieberman JA, Tollefson GD, Charles C, Zipursky R, Sharma T, Kahn RS, et al HGDH Study Group. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch Gen Psychiatry 2005;62:361-370. (Pubitemid 40471685)
68. Crespo-Facorro B, Roiz-Santiáñez R, Pérez-Iglesias R, Pelayo-Terán JM, Rodríguez-Sánchez JM, Tordesillas-Gutié rrez D, et al. Effect of antipsychotic drugs on brain morphometry. A randomized controlled one-year follow-up study of haloperidol, risperidone and olanzapine. Prog Neuropsychopharmacol Biol Psychiatry 200832:1936-1943
69. National Institute for Clinical Excellence. Schizophrenia. NICE Clinical Guideline 82. London:NICE;2009
70. Manchanda R, Norman RM, Malla AK, Harricharan R, Northcott S. Persistent psychoses in first episode patients. Schizophr Res 2005;80:113-116. (Pubitemid 41587469)
71. Lieberman JA, Phillips M, Gu H, Stroup S, Zhang P, Kong L, et al. Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology 200328:995-1003
72. Woerner MG, Robinson DG, Alvir JM, Sheitman BB, Lieberman JA, Kane JM. Clozapine as a first treatment for schizophrenia. Am J Psychiatry 2003;160:1514-1516. (Pubitemid 41070929)
73. Agid O, Arenovich T, Sajeev G, Zipursky RB, Kapur S, Foussias G, et al. An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis. J Clin Psychiatry 201172:1439-1444
74. Agid O, Remington G, Kapur S, Arenovich T, Zipursky RB. Early use of clozapine for poorly responding first-episode psychosis. J Clin Psychopharmacol 2007;27:369-373. (Pubitemid 47075508)
75. Zhang ZJ, Chen YC, Wang HN, Wang HH, Xue YY, Feng SF, et al. Electroconvulsive therapy improves antipsychotic and somnographic responses in adolescents with first-episode psychosis - A case-control study. Schizophr Res 2012137:97-103
76. Suzuki K, Awata S, Takano T, Ebina Y, Takamatsu K, Kajiwara T, et al. Improvement of psychiatric symptoms after electroconvulsive therapy in young adults with intractable first-episode schizophrenia and schizophreniform disorder. Tohoku J Exp Med 2006;210:213-220. (Pubitemid 44697264)
77. Ohlsen RI, O'Toole MS, Purvis RG, Walters JT, Taylor TM, Jones HM, et al. Clinical effectiveness in first-episode patients. Eur Neuropsychopharmacol 2004;14(Suppl 4):S445-S451. (Pubitemid 39574336)
78. Penn DL, Waldheter EJ, Perkins DO, Mueser KT, Lieberman JA. Psychosocial treatment for first-episode psychosis: a research update. Am J Psychiatry 2005;162:2220-2232. (Pubitemid 41740199)
79. Crespo-Facorro B, Pérez-Iglesias R, González-Blanch C, Mata I. Treatment of the first episode of schizophrenia: an update on pharmacologic and psychological interventions. Curr Psychiatry Rep 200810:202-209
80. Askey R, Gamble C, Gray R. Family work in first-onset psychosis: a literature review. J Psychiatr Ment Health Nurs 200714:356-365